The Technical Analyst
Aravive Inc [ARAV]
Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology
Aravive Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.66% $1.123
Last updated: 16 May 2022 @ 10:36 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 32.36 mill |
| EPS: | -1.951 |
| P/E: | 0.000 |
| Earnings Date: | Aug 03, 2022 |
| SharesOutstanding: | 28.82 mill |
| Avg Daily Volume: | 0.0612 mill |
| RATING 2022-05-13 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.89 (335.27%) $3.76 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $0.156 ( +/- 14.18%) Range: 0.944 - 1.256 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-04-01 | Eshelman Fredric N | Buy | 4 545 455 | Pre-Funded Warrant (right to buy) |
| 2022-04-01 | Eshelman Fredric N | Buy | 4 545 455 | Common Stock |
| 2022-03-29 | Eshelman Fredric N | Buy | 860 216 | Warrant (right to buy) |
| 2022-03-29 | Eshelman Fredric N | Buy | 860 216 | Common Stock |
| 2022-03-21 | Dove Leonard Scott | Buy | 200 000 | Stock Option (Right to buy) |
| INSIDER POWER |
|---|
| 93.08 |
| Last 100 transactions |
| Buy: 22 638 611 | Sell: 189 482 |
Forecast:
11:45 - $1.126
Live Trading Signals (every 1 min)
Forecast
1: 10:15 - $1.122
Forecast 2: 11:05 - $1.109
Forecast 3: 11:45 - $1.126
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.123 (-0.66% ) |
| Volume | 0.0180 mill |
| Avg. Vol. | 0.0612 mill |
| % of Avg. Vol | 29.42 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
ARAV
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Latest Press Releases
2022-04-29 07:00:00 - Press Release
Aravive Announces Poster Presentations At The 2022 Asco Annual Meeting
Houston, april 29, 2022 (globe newswire) -- aravive, inc. (nasdaq: arav), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of two poster abstracts at the upcoming american society of clinical oncology (asco) 2022 annual meeting, to be held in-person on june 3-7, 2022 in chicago, illinois. notably, abstract number 4511 was selected for an oral presentation as part of a poster discussion session.
2022-04-01 07:00:00 - Press Release
Aravive Announces Closing Of $10 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
Houston, april 01, 2022 (globe newswire) -- aravive, inc. (nasdaq: arav), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has closed its previously announced registered direct offering priced at-the-market under nasdaq rules with a single healthcare-focused institutional investor and eshelman ventures, llc. in the offering, aravive issued and sold an aggregate of 4,850,241 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,850,241 shares of common stock. the purchase price per share and accompanying warrant was $2.005 for the institutional investor and $2...
2022-03-31 16:05:00 - Press Release
Aravive Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates
Houston, march 31, 2022 (globe newswire) -- aravive, inc. (nasdaq: arav, “the company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced fourth quarter and full year ended december 31, 2021 financial results and provided corporate updates.
2022-03-30 08:00:00 - Press Release
Aravive Announces $10 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
Houston, march 30, 2022 (globe newswire) -- aravive, inc. (nasdaq: arav), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it has entered into definitive agreements with a single healthcare-focused institutional investor and eshelman ventures, llc for the issuance and sale of an aggregate of 4,850,241 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,850,241 shares of common stock in a registered direct offering priced at-the-market under nasdaq rules. the purchase price per share and accompanying warrant is $2.005 for the institutional investor and $2...
2022-03-07 07:00:00 - Press Release
Aravive To Participate In-person At 34th Annual Roth Conference
Houston, march 07, 2022 (globe newswire) -- aravive, inc. (nasdaq: arav), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that gail mcintyre, ph.d., dabt, chief executive officer of aravive, will participate in an in-person fireside chat at the 34th annual roth conference on monday, march 14, 2022, at 8:30 am pt in healthcare vfc – suite 2022 at the ritz carlton, dana point, california. dr. mcintyre and vinay shah, chief financial officer of aravive, will be available for one-on-one meetings on monday, march 14th.
Latest News
2022-05-12 09:47:30 - Zacks Investment Research
Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates
Aravive (ARAV) delivered earnings and revenue surprises of -16.98% and 2.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-03-31 18:48:16 - Zacks Investment Research
Aravive (ARAV) Reports Q4 Loss, Misses Revenue Estimates
Aravive (ARAV) delivered earnings and revenue surprises of 3.12% and 36.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2022-03-03 10:06:00 - Benzinga
Aravive Highlights Updated Batiraxcept Data From Kidney Cancer Trial
Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC). 26 previously treated ccRCC patients have been treated with batiraxcept at doses of 15 mg/kg (n=16) and 20 mg/kg (n=10.
2022-03-02 07:00:00 - GlobeNewsWire
Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting
HOUSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposure-response analyses from the Phase 1b platinum-resistant ovarian cancer and Phase 1b clear cell renal cancer trials at the American Association for Cancer Research (AACR) annual meeting taking place between April 8-13, 2022 in New Orleans, Louisiana. The abstract presentation at AACR will be presented virtually.
2022-02-10 13:05:09 - Zacks Investment Research
Aravive (ARAV) Upgraded to Buy: Here's Why
Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-02-10 10:46:11 - Zacks Investment Research
Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?
Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
2021-10-28 19:51:21 - Zacks Investment Research
Aravive (ARAV) Reports Q3 Loss, Tops Revenue Estimates
Aravive (ARAV) delivered earnings and revenue surprises of -26.19% and 2.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-09-16 07:00:00 - GlobeNewsWire
Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference
HOUSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021 at 9:20 AM ET. Aravive will also participate in one-on-one meetings at the conference.
2021-09-01 07:00:00 - GlobeNewsWire
Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The Company's presentation will be available for viewing on September 13, 2021 at 7:00 AM ET. Aravive will also participate in one-on-one meetings at the conference.
2021-07-27 07:00:00 - GlobeNewsWire
Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference
HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 BTIG Biotechnology Conference on August 9, 2021, at 9:30 AM ET. Aravive will also be participating in one-on-one meetings at the conference.